These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28464572)

  • 41. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
    Carlsson SV; de Carvalho TM; Roobol MJ; Hugosson J; Auvinen A; Kwiatkowski M; Villers A; Zappa M; Nelen V; Páez A; Eastham JA; Lilja H; de Koning HJ; Vickers AJ; Heijnsdijk EA
    Cancer; 2016 Nov; 122(21):3386-3393. PubMed ID: 27459245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
    Jonsson H; Holmström B; Duffy SW; Stattin P
    Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016.
    Molazem Z; Ebadi M; Khademian M; Zare R
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of increasing detection in the rising incidence of prostate cancer.
    Potosky AL; Miller BA; Albertsen PC; Kramer BS
    JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pathology consultation on prostate-specific antigen testing.
    Noguez JH; Fantz CR
    Am J Clin Pathol; 2014 Jul; 142(1):7-15. PubMed ID: 24926079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
    Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.
    Van der Meer S; Kollen BJ; Hirdes WH; Steffens MG; Hoekstra-Weebers JE; Nijman RM; Blanker MH
    BJU Int; 2013 Jul; 112(1):26-31. PubMed ID: 23465178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinicians' perceptions of the benefits and harms of prostate and colorectal cancer screening.
    Elstad EA; Sutkowi-Hemstreet A; Sheridan SL; Vu M; Harris R; Reyna VF; Rini C; Earp JA; Brewer NT
    Med Decis Making; 2015 May; 35(4):467-76. PubMed ID: 25637592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Incidence of prostate cancer in Lithuania after introduction of the Early Prostate Cancer Detection Programme.
    Smailyte G; Aleknaviciene B
    Public Health; 2012 Dec; 126(12):1075-7. PubMed ID: 22381571
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSA testing in Austria: induced morbidity and saved mortality.
    Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
    Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baseline prostate-specific antigen testing at a young age.
    Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
    Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.
    McHugh J; Saunders EJ; Dadaev T; McGrowder E; Bancroft E; Kote-Jarai Z; Eeles R
    Br J Cancer; 2022 Jun; 126(10):1366-1373. PubMed ID: 34923574
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China.
    Zhang L; Wu S; Guo LR; Zhao XJ
    Asian J Androl; 2009 Jan; 11(1):9-13. PubMed ID: 19050685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PSA testing, cancer treatment, and prostate cancer mortality reduction: What is the mechanism?
    Albertsen PC
    Urol Oncol; 2023 Feb; 41(2):78-81. PubMed ID: 34497024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Epidemiology of prostate cancer in China: an overview and clinical implication].
    Ye D; Zhu Y
    Zhonghua Wai Ke Za Zhi; 2015 Apr; 53(4):249-52. PubMed ID: 26269155
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.